Late Stage Chronic Kidney Disease Drugs Market Report 2025

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.08 billion in 2024 to $7.86 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development.

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $12.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for CKD management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.

The forecast of 11.4% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. nephrology centers by increasing costs of erythropoiesis-stimulating agents and phosphate binders imported from the UK and Ireland, potentially reducing dialysis outcomes and raising renal care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The high prevalence of chronic kidney diseases is expected to drive the growth of the late-stage chronic kidney disease drug market in the future. Chronic kidney diseases encompass a wide range of conditions that impact the structure and function of the kidneys. Drugs for late-stage chronic kidney disease are utilized to manage blood pressure in patients and reduce protein loss, helping to slow the progression of kidney impairment, alleviate symptoms, and prevent complications. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, estimated that approximately 14% of U.S. adults - around 35.5 million people - are living with chronic kidney diseases. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.

The increasing prevalence of diabetes is anticipated to drive the growth of the late-stage chronic kidney disease (CKD) drug market in the future. Diabetes is a chronic condition marked by elevated blood glucose levels, which can cause significant damage to the heart, blood vessels, eyes, kidneys, and nerves. It is a well-recognized risk factor for developing chronic kidney disease. Individuals with diabetes, particularly those with poorly managed blood sugar levels, face a heightened risk of progressing to late-stage CKD. As the global prevalence of diabetes rises, the incidence of CKD, especially in its advanced stages, is expected to rise correspondingly. For example, in March 2024, the Office for Health Improvement & Disparities, a UK government department, reported that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of patients achieving target HbA1c levels rose to 37.9%, marking the highest level recorded by the National Diabetes Audit (NDA). Therefore, the high prevalence of diabetes is propelling the growth of the late-stage chronic kidney disease drug market.

Product innovation emerges as a prominent trend gaining traction in the late-stage chronic kidney disease drug market, with major companies actively developing new drugs to maintain their market positions. For example, in February 2022, Bayer, a leading Germany-based pharmaceutical and biotechnology company, introduced Kerendia (finerenone) in India. Finerenone, a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, is recommended for patients with type two diabetes and chronic renal disease. The drug works by preventing the overactivation of the mineralocorticoid receptor (MR), believed to be a factor in the development of chronic kidney disease (CKD) and cardiovascular harm.

Key players in the late-stage chronic kidney disease drugs market are advancing technologies such as continuous subcutaneous infusion methods to enhance treatment effectiveness, improve patient outcomes, and streamline the drug development process. Continuous subcutaneous infusion technology provides a steady delivery of medication through a small device implanted under the skin, ensuring consistent therapeutic levels and increasing patient adherence. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, introduced PRODUODOPA (for levodopa/foscarbidopa). This product facilitates a continuous infusion of levodopa, which is essential for maintaining stable dopamine levels in the bloodstream. This is vital for effectively managing symptoms, as it prolongs the duration of on time - periods when symptoms are well-managed - while reducing off time when symptoms reappear.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. This strategic acquisition strengthens AstraZeneca's cardiorenal pipeline by adding CinCor's potential medication, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) designed to treat chronic kidney disorders. CinCor Pharma Inc., a US-based clinical-stage biopharmaceutical company, is the developer of baxdrostat. The acquisition enhances AstraZeneca's position in the late-stage chronic kidney disease drug market.

Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc.

North America was the largest region in the late stage chronic kidney disease drugs market in 2024. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The late stage chronic kidney disease drugs market research report is one of a series of new reports that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Late-stage chronic kidney disease drugs are medications designed to treat end-stage chronic kidney disease, aiming to improve patients' quality of life by arresting the progression of the disease and, in some cases, preventing or delaying the need for dialysis or a kidney transplant.

The primary product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics, for instance, constitute a class of medications that enhance signaling and reduce parathyroid hormone (PTH) levels by activating the calcium-sensing receptor allosterically. These drugs address various indications related to late-stage chronic kidney disease, such as hyperparathyroidism, hyperphosphatemia, and hyperkalemia. The distribution channels for these drugs typically include hospital pharmacies, online pharmacies, and retail pharmacies.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.